MNG355
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.397
- PANCREAS_BETA_CELLS+0.376
- KRAS_SIGNALING_DN+0.355
- SPERMATOGENESIS+0.247
- ESTROGEN_RESPONSE_LATE+0.182
- ESTROGEN_RESPONSE_EARLY+0.173
- BILE_ACID_METABOLISM+0.146
- COAGULATION+0.098
- APICAL_JUNCTION+0.059
- APICAL_SURFACE+0.052
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.604
- MYC_TARGETS_V2-0.577
- DNA_REPAIR-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.457
- MYC_TARGETS_V1-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.416
- ADIPOGENESIS-0.406
- IL6_JAK_STAT3_SIGNALING-0.371
- MTORC1_SIGNALING-0.371
- INTERFERON_ALPHA_RESPONSE-0.327
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KPT2WPHW | Ganglioglioma | — | 0.914 |
| 2 | BS_CQSAJ7BF | DNET | — | 0.910 |
| 3 | C3N-03921 | — | cohortA1 | 0.908 |
| 4 | BS_K5802F84 | pilocytic astrocytoma | — | 0.900 |
| 5 | SRR1329090 | GTEX | — | 0.897 |
| 6 | BS_A14Z8BBK | Med | Medulloblastoma | 0.896 |
| 7 | SRR1362417 | GTEX | — | 0.895 |
| 8 | BS_92VDQ0NE | Ganglioglioma | — | 0.894 |
| 9 | MNG786 | — | — | 0.894 |
| 10 | BS_3T6X4BPC | DNET | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.397 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.376 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.355 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.247 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.182 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.173 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.146 | Inavolisib | — uncovered |
| COAGULATION | 0.098 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.059 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.052 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.049 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.045 | Inavolisib | — uncovered |